These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 33200774)
1. Interstitial Lung Disease and Myositis in a Patient With Antisynthetase Syndrome and PL12 and Ro52 Co-positivity in a Retired Medical Officer. Loncharich MF; Anderson CW; Collins J; Edison J Mil Med; 2021 Jul; 186(7-8):e836-e839. PubMed ID: 33200774 [TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics and prognostic analysis of idiopathic inflammatory myopathy with positive anti-aminoacyl-tRNA synthetase antibodies: A single center experience. Zhang D; Wang H; Zhou X; Yang J; Liu Y; Wang W; Jiang P; Fan B Immun Inflamm Dis; 2023 Nov; 11(11):e1085. PubMed ID: 38018600 [TBL] [Abstract][Full Text] [Related]
4. Clinical Profiles and Prognosis of Patients with Distinct Antisynthetase Autoantibodies. Shi J; Li S; Yang H; Zhang Y; Peng Q; Lu X; Wang G J Rheumatol; 2017 Jul; 44(7):1051-1057. PubMed ID: 28461650 [TBL] [Abstract][Full Text] [Related]
5. Phenotypic Profiles Among 72 Caucasian and Afro-Caribbean Patients with Antisynthetase Syndrome Involving Anti-PL7 or Anti-PL12 Autoantibodies. Abel A; Lazaro E; Ralazamahaleo M; Pierrisnard E; Suzon B; Bonnet F; Mercié P; Macey J; Agossou M; Viallard JF; Deligny C; Rivière E Eur J Intern Med; 2023 Sep; 115():104-113. PubMed ID: 37330316 [TBL] [Abstract][Full Text] [Related]
6. Presentations and outcomes of interstitial lung disease and the anti-Ro52 autoantibody. Sclafani A; D'Silva KM; Little BP; Miloslavsky EM; Locascio JJ; Sharma A; Montesi SB Respir Res; 2019 Nov; 20(1):256. PubMed ID: 31718649 [TBL] [Abstract][Full Text] [Related]
7. Clinical characterisation of a multicentre nationwide cohort of patients with antisynthetase syndrome. Martins P; Dourado E; Melo AT; Samões B; Sousa M; Freitas R; Lourenço MH; Fernandes B; Costa E; Parente H; Martins F; Fonseca JE; Cordeiro I; Romão VC; Khmelinskii N; Campanilho-Marques R ARP Rheumatol; 2022 Nov; 1(ARP Rheumatology, nº3 2022):190-196. PubMed ID: 35891592 [TBL] [Abstract][Full Text] [Related]
8. Rituximab in the Treatment of Jo1 Antibody-associated Antisynthetase Syndrome: Anti-Ro52 Positivity as a Marker for Severity and Treatment Response. Bauhammer J; Blank N; Max R; Lorenz HM; Wagner U; Krause D; Fiehn C J Rheumatol; 2016 Aug; 43(8):1566-74. PubMed ID: 27252419 [TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of patients with anti-EJ antisynthetase syndrome associated interstitial lung disease and literature review. Liu Y; Liu X; Xie M; Chen Z; He J; Wang Z; Dai J; Cai H Respir Med; 2020; 165():105920. PubMed ID: 32174452 [TBL] [Abstract][Full Text] [Related]
10. Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome. Marie I; Josse S; Decaux O; Dominique S; Diot E; Landron C; Roblot P; Jouneau S; Hatron PY; Tiev KP; Vittecoq O; Noel D; Mouthon L; Menard JF; Jouen F Autoimmun Rev; 2012 Aug; 11(10):739-45. PubMed ID: 22326685 [TBL] [Abstract][Full Text] [Related]
11. Short-term and long-term outcome of anti-Jo1-positive patients with anti-Ro52 antibody. Marie I; Hatron PY; Dominique S; Cherin P; Mouthon L; Menard JF; Levesque H; Jouen F Semin Arthritis Rheum; 2012 Jun; 41(6):890-9. PubMed ID: 22078416 [TBL] [Abstract][Full Text] [Related]
12. Idiopathic inflammatory myopathies: CT characteristics of interstitial lung disease and their association(s) with myositis-specific autoantibodies. Laporte A; Mariampillai K; Allenbach Y; Pasi N; Donciu V; Toledano D; Granger B; Benveniste O; Grenier PA; Boussouar S Eur Radiol; 2022 May; 32(5):3480-3489. PubMed ID: 35022809 [TBL] [Abstract][Full Text] [Related]
13. Association of anti-Ro52 autoantibody with interstitial lung disease in autoimmune diseases: a systematic review and meta-analysis. Nayebirad S; Mohamadi A; Yousefi-Koma H; Javadi M; Farahmand K; Atef-Yekta R; Tamartash Z; Jameie M; Mohammadzadegan AM; Kavosi H BMJ Open Respir Res; 2023 Nov; 10(1):. PubMed ID: 38030264 [TBL] [Abstract][Full Text] [Related]
14. [Clinical characteristics of patients with antisynthetase syndrome and positive anti-Ro52 antibody]. Zhang X; Zhao XM; Yang QH; Lian CF; Li W; Yang L; Lu JM; Guan WJ; Zhang LJ; Cheng SH; Li H; Liu SY Zhonghua Nei Ke Za Zhi; 2022 Feb; 61(2):200-204. PubMed ID: 35090256 [TBL] [Abstract][Full Text] [Related]
15. A longitudinal cohort study of the anti-synthetase syndrome: increased severity of interstitial lung disease in black patients and patients with anti-PL7 and anti-PL12 autoantibodies. Pinal-Fernandez I; Casal-Dominguez M; Huapaya JA; Albayda J; Paik JJ; Johnson C; Silhan L; Christopher-Stine L; Mammen AL; Danoff SK Rheumatology (Oxford); 2017 Jun; 56(6):999-1007. PubMed ID: 28339994 [TBL] [Abstract][Full Text] [Related]
17. The differential role of SSa/SSb and Ro52 antibodies in defining clinical phenotypes in idiopathic inflammatory myopathies. Valle A; Narain S; Barilla-Labarca ML; Marder G Semin Arthritis Rheum; 2024 Apr; 65():152407. PubMed ID: 38377624 [TBL] [Abstract][Full Text] [Related]
18. A 64-year-old woman with interstitial lung disease and positive antibodies against aminoacyl-transfer RNA synthetases in the absence of myositis: presentation of an anti-PL-12 positive antisynthetase syndrome. Ghysen K; Leys M Acta Clin Belg; 2018 Oct; 73(5):389-392. PubMed ID: 29173135 [TBL] [Abstract][Full Text] [Related]
19. Clinical Characteristics of Anti-Synthetase Syndrome and Variables Associated with Interstitial Lung Disease and Mortality: A Retrospective Cohort Study. Sodsri T; Petnak T; Ngamjanyaporn P J Clin Med; 2023 Oct; 12(21):. PubMed ID: 37959314 [TBL] [Abstract][Full Text] [Related]